FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162192407> ?p ?o ?g. }

• W3162192407 endingPage "840" @default.
• W3162192407 startingPage "833" @default.
• W3162192407 abstract "Mesenchymal stromal cells (MSCs) are characterized by paracrine and immunomodulatory functions capable of changing the microenvironment of damaged brain tissue toward a more regenerative and less inflammatory milieu. The authors conducted a phase 2, single-center, assessor-blinded randomized controlled trial to investigate the safety and efficacy of intravenous autologous bone marrow-derived MSCs (BMMSCs) in patients with subacute middle cerebral artery (MCA) infarct.Patients aged 30-75 years who had severe ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score of 10-35) involving the MCA territory were recruited within 2 months of stroke onset. Using permuted block randomization, patients were assigned to receive 2 million BMMSCs per kilogram of body weight (treatment group) or standard medical care (control group). The primary outcomes were the NIHSS, modified Rankin Scale (mRS), Barthel Index (BI) and total infarct volume on brain magnetic resonance imaging (MRI) at 12 months. All outcome assessments were performed by blinded assessors. Per protocol, analyses were performed for between-group comparisons.Seventeen patients were recruited. Nine were assigned to the treatment group, and eight were controls. All patients were severely disabled following their MCA infarct (median mRS = 4.0 [4.0-5.0], BI = 5.0 [5.0-25.0], NIHSS = 16.0 [11.5-21.0]). The baseline infarct volume on the MRI was larger in the treatment group (median, 71.7 [30.5-101.7] mL versus 26.7 [12.9-75.3] mL, P = 0.10). There were no between-group differences in median NIHSS score (7.0 versus 6.0, P = 0.96), mRS (2.0 versus 3.0, P = 0.38) or BI (95.0 versus 67.5, P = 0.33) at 12 months. At 12 months, there was significant improvement in absolute change in median infarct volume, but not in total infarct volume, from baseline in the treatment group (P = 0.027). No treatment-related adverse effects occurred in the BMMSC group.Intravenous infusion of BMMSCs in patients with subacute MCA infarct was safe and well tolerated. Although there was no neurological recovery or functional outcome improvement at 12 months, there was improvement in absolute change in median infarct volume in the treatment group. Larger, well-designed studies are warranted to confirm this and the efficacy of BMMSCs in ischemic stroke." @default.
• W3162192407 created "2021-05-24" @default.
• W3162192407 creator A5006940190 @default.
• W3162192407 creator A5007876439 @default.
• W3162192407 creator A5008107091 @default.
• W3162192407 creator A5024388155 @default.
• W3162192407 creator A5036023513 @default.
• W3162192407 creator A5036687729 @default.
• W3162192407 creator A5043698430 @default.
• W3162192407 creator A5044158905 @default.
• W3162192407 creator A5044900807 @default.
• W3162192407 creator A5051469085 @default.
• W3162192407 creator A5076873364 @default.
• W3162192407 creator A5080878492 @default.
• W3162192407 date "2021-09-01" @default.
• W3162192407 modified "2023-10-08" @default.
• W3162192407 title "The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and efficacy" @default.
• W3162192407 cites W1550049909 @default.
• W3162192407 cites W1984879417 @default.
• W3162192407 cites W1989560466 @default.
• W3162192407 cites W1989622931 @default.
• W3162192407 cites W2004231870 @default.
• W3162192407 cites W2004872316 @default.
• W3162192407 cites W2004995152 @default.
• W3162192407 cites W2027898925 @default.
• W3162192407 cites W2029584195 @default.
• W3162192407 cites W2048416790 @default.
• W3162192407 cites W2073190583 @default.
• W3162192407 cites W2100975089 @default.
• W3162192407 cites W2106184691 @default.
• W3162192407 cites W2108896478 @default.
• W3162192407 cites W2118993793 @default.
• W3162192407 cites W2120377232 @default.
• W3162192407 cites W2121567769 @default.
• W3162192407 cites W2125632594 @default.
• W3162192407 cites W2127890285 @default.
• W3162192407 cites W2142111423 @default.
• W3162192407 cites W2145864353 @default.
• W3162192407 cites W2155945484 @default.
• W3162192407 cites W2161648295 @default.
• W3162192407 cites W2170263306 @default.
• W3162192407 cites W2262333767 @default.
• W3162192407 cites W2277258071 @default.
• W3162192407 cites W2535380243 @default.
• W3162192407 cites W2557703475 @default.
• W3162192407 cites W2568954699 @default.
• W3162192407 cites W2780149673 @default.
• W3162192407 cites W2801269890 @default.
• W3162192407 cites W2801559469 @default.
• W3162192407 cites W2802982793 @default.
• W3162192407 cites W2921298720 @default.
• W3162192407 cites W2973154975 @default.
• W3162192407 cites W2982104105 @default.
• W3162192407 cites W2996675659 @default.
• W3162192407 cites W3032073814 @default.
• W3162192407 cites W3040826183 @default.
• W3162192407 cites W3088343539 @default.
• W3162192407 doi "https://doi.org/10.1016/j.jcyt.2021.03.005" @default.
• W3162192407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33992536" @default.
• W3162192407 hasPublicationYear "2021" @default.
• W3162192407 type Work @default.
• W3162192407 sameAs 3162192407 @default.
• W3162192407 citedByCount "20" @default.
• W3162192407 countsByYear W31621924072022 @default.
• W3162192407 countsByYear W31621924072023 @default.
• W3162192407 crossrefType "journal-article" @default.
• W3162192407 hasAuthorship W3162192407A5006940190 @default.
• W3162192407 hasAuthorship W3162192407A5007876439 @default.
• W3162192407 hasAuthorship W3162192407A5008107091 @default.
• W3162192407 hasAuthorship W3162192407A5024388155 @default.
• W3162192407 hasAuthorship W3162192407A5036023513 @default.
• W3162192407 hasAuthorship W3162192407A5036687729 @default.
• W3162192407 hasAuthorship W3162192407A5043698430 @default.
• W3162192407 hasAuthorship W3162192407A5044158905 @default.
• W3162192407 hasAuthorship W3162192407A5044900807 @default.
• W3162192407 hasAuthorship W3162192407A5051469085 @default.
• W3162192407 hasAuthorship W3162192407A5076873364 @default.
• W3162192407 hasAuthorship W3162192407A5080878492 @default.
• W3162192407 hasBestOaLocation W31621924072 @default.
• W3162192407 hasConcept C126322002 @default.
• W3162192407 hasConcept C126838900 @default.
• W3162192407 hasConcept C127413603 @default.
• W3162192407 hasConcept C141071460 @default.
• W3162192407 hasConcept C143409427 @default.
• W3162192407 hasConcept C168563851 @default.
• W3162192407 hasConcept C1862650 @default.
• W3162192407 hasConcept C197934379 @default.
• W3162192407 hasConcept C2775841333 @default.
• W3162192407 hasConcept C2776361831 @default.
• W3162192407 hasConcept C2778375690 @default.
• W3162192407 hasConcept C2778818304 @default.
• W3162192407 hasConcept C2780645631 @default.
• W3162192407 hasConcept C2780931571 @default.
• W3162192407 hasConcept C3020199598 @default.
• W3162192407 hasConcept C541997718 @default.
• W3162192407 hasConcept C71924100 @default.
• W3162192407 hasConcept C78519656 @default.
• W3162192407 hasConceptScore W3162192407C126322002 @default.

• next